The disease in the author’s household never had a clinical label. It had behaviors: hands that shook, words that disappeared mid-sentence, presence at breakfast and absence by dinner. Those details structured daily life for three generations — the grandmother, the mother, the older sister — across roughly fifty years of family history documented in medical encounters.
Doctors, the family was told repeatedly, described the condition as rare, poorly understood, and difficult to characterize. The language became a fact of life. The family used a pronoun instead of a name. The pronoun shaped caregiving patterns: the author became the primary caregiver from about age eight, managing household tasks and translating the family’s interior experience into what the world could understand. The sentence that mattered most — that no one knew — hardened into the family’s reality.
The author is a research methodologist with more than two decades spent building systematic reviews and following citation chains. She had the skills and institutional access to search the literature. Still, she stopped looking; years of clinical shrugging had convinced her that the absence of a name was the settled state. Grief and long-term caregiving produced an exhaustion that tamped down active inquiry.
After finishing a memoir titled “Naming It,” she revisited old documents. The oldest was her grandmother’s death certificate with cause listed as acute coronary thrombosis — a catchall, not an explanatory diagnosis for the neurological course seen in the family. The author then used an AI-assisted search (she mentioned using Claude) and fed it the family clinical details alongside literature from the 1980s and 1990s. Within seconds, the search brought a match: FENIB — familial encephalopathy with neuroserpin inclusion bodies — an ultra-rare genetic neurodegenerative disorder characterized by progressive dementia and seizures.
The literature, the author found, had named and studied the condition for years. Research groups had described cases; the family’s pattern appeared in the published record. The condition’s prevalence is described in the literature as affecting fewer than 1 in 1 million people. What had been a pronoun within the household now had a diagnostic label in the scientific record: FENIB.
Learning the diagnostic label did more than satisfy curiosity. The author writes that the name rearranged the meaning of decades of events. A set of previously disconnected observations fell into pattern: the progressive cognitive decline, the seizures, the intergenerational transmission. Armed with a name, the author could tell her children the truth directly; she describes doing so at a restaurant on an ordinary Wednesday, sharing the death certificate, the research, and the name she found.
This generational handoff matters clinically and emotionally. For the author’s children, the disease will no longer be an unnamed inheritance passed down as a pronoun but a condition with a label that can be referenced in medical records, genetic counseling conversations, and future clinical decision making.
The essay emphasizes a structural problem: clinical research and published case reports often remain siloed in databases and journals, without reliable mechanisms to notify patients or families whose records contributed to that literature. Investigators reported findings; the cohort showed results; the study teams published. But the loop from research back to families frequently remains open on the family side and closed in the academic archive.
The author explicitly frames this as an infrastructure failure rather than malfeasance. She points out two concrete gaps: historical research participants lack a guaranteed right to follow-up notification, and families who contributed cases may never learn that a paper naming their condition exists. The cost is real in human terms — the author cites nearly 40 years of illness for her mother without being told that researchers had characterized the disease, and her sister’s 15 years of deterioration followed by death at 41 in a world where answers existed in publications that never reached them.
The author has written a memoir, “Naming It,” which framed her return to documents and literature. After that work, she used the evidence she assembled to inform next steps within her family: disclosure to her children and the possibility of different clinical choices for future generations.
She leaves readers with specific, documented concerns rather than a broad summation. The essay identifies unanswered operational questions: which mechanisms should notify families when a condition is named? Who is responsible for ensuring longitudinal follow-up of research participants in rare-disease cohorts? The source does not report policy fixes, trial details, or concrete regulatory milestones; it documents instead a persistent gap between published medical knowledge and the families who live with the conditions described.
The narrative ends with the family newly carrying a name instead of a pronoun and with an open question about how often other families remain disconnected from the literature that describes them — a problem the author attributes to infrastructure rather than intent and one the article leaves as an actionable point for medical systems and researchers to address.